Global microRNA profiling in favorable prognosis subgroups of cancer of unknown primary (CUP) demonstrates no significant expression differences with metastases of matched known primary tumors

Clinical and Experimental Metastasis

Volumn 30, Issue 4, 2013, Pages 431-439

  Pentheroudakis, George ^a   Spector, Yael ^b   Krikelis, Dimitrios ^c   Kotoula, Vassiliki ^c   Meiri, Eti ^b   Malamou Mitsi, Vassiliki ^a   Fountzilas, George ^c   Sanden, Mats ^d   Pavlidis, Nicholas ^a   Benjamin, Hila ^b   Aharonov, Ranit ^b  

^a UNIVERSITY OF IOANNINA   (Greece)

^b ROSETTA GENOMICS LTD   (Israel)

^c ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^d Rosetta Genomics Inc   (United States)

Author keywords

Cancer of unknown primary; Gene expression; MicroRNA

Indexed keywords

MICRORNA; MICRORNA 106A; MICRORNA 125A-5P; MICRORNA 143; MICRORNA 149; MICRORNA 17; MICRORNA 18A; MICRORNA 1972; MICRORNA 20A; MICRORNA 27B; MICRORNA 29C; MICRORNA 30E; MICRORNA 331-3P; MICRORNA 483-5P; MICRORNA 513A-5P; MICRORNA 574-3P; MICRORNA 708; MICRORNA 92A; MICRORNA 92B; UNCLASSIFIED DRUG;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; BREAST ADENOCARCINOMA; CANCER OF UNKNOWN PRIMARY SITE; CANCER PROGNOSIS; CARCINOMATOUS PERITONITIS; CERVICAL LYMPHADENOPATHY; CLINICAL ARTICLE; COMPARATIVE STUDY; DOWN REGULATION; FEMALE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; LUNG SQUAMOUS CELL CARCINOMA; MALE; MICROARRAY ANALYSIS; OVARY CARCINOMA; PRIMARY TUMOR; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; UPREGULATION;

ADENOCARCINOMA; ADULT; AGED; BREAST NEOPLASMS; CARCINOMA, SQUAMOUS CELL; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HEAD AND NECK NEOPLASMS; HUMANS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASMS, UNKNOWN PRIMARY; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 84876473020     PISSN: 02620898     EISSN: 15737276     Source Type: Journal    
DOI: 10.1007/s10585-012-9548-3     Document Type: Article

References (37)

1. Pavlidis N, Pentheroudakis G (2012) Cancer of unknown primary site. Lancet 379:1428-1435
2. Pentheroudakis G, Briasoulis E, Pavlidis N (2007) Cancer of unknown primary site: missing primary or missing biology? Oncologist 12:418-425
3. Monzon FA, Koen TJ (2010) Diagnosis of metastatic neoplasms: molecular approaches for identification of tissue of origin. Arch Pathol Lab Med 134:216-224
4. Pavlidis N, Petrakis D, Golfinopoulos V, Pentheroudakis G (2012) Long-term survivors among patients with cancer of unknown primary. Crit Rev Oncol Hematol 84(1):85-92
5. Pentheroudakis G, Stoyianni A, Pavlidis N (2011) Cancer of unknown primary patients with midline nodal distribution: midway between poor and favourable prognosis? Cancer Treat Rev 37:120-126
6. Pentheroudakis G, Pavlidis N (2010) Serous papillary peritoneal carcinoma: unknown primary tumour, ovarian cancer counterpart or a distinct entity? A systematic review. Crit Rev Oncol Hematol 75:27-42
7. Pentheroudakis G, Lazaridis G, Pavlidis N (2010) Axillary nodal metastases from carcinoma of unknown primary (CUPAx): a systematic review of published evidence. Breast Cancer Res Treat 119:1-11
8. Barad O, Meiri E, Avniel A et al (2004) MicroRNA expression detected by oligonucleotide microarrays: system establishment and expression profiling in human tissues. Genome Res 14:2486-2494
9. Varadhachary GR, Spector Y, Abbruzzese JL et al (2011) Prospective gene signature study using microRNA to identify the tissue of origin in patients with carcinoma of unknown primary. Clin Cancer Res 17:4063-4070
10. Meiri E, Mueller WC, Rosenwald S et al (2012) A second-generation microRNA-based assay for diagnosing tumor tissue origin. Oncologist 17:801-812
11. Nass D, Rosenwald S, Meiri E et al (2009) MiR-92b and miR-9/9*are specifically expressed in brain primary tumors and can be used to differentiate primary from metastatic brain tumors. Brain Pathol 19:375-383
12. Benjamini Y, Drai D, Elmer G et al (2001) Controlling the false discovery rate in behavior genetics research. Behav Brain Res 125:279-284
13. Clark-Langone KM, Sangli C, Krishnakumar J, Watson D (2010) Translating tumor biology into personalized treatment planning: analytical performance characteristics of the Oncotype DX Colon Cancer Assay. BMC Cancer 10:691
14. Joh JE, Esposito NN, Kiluk JV et al (2011) The effect of Oncotype DX recurrence score on treatment recommendations for patients with estrogen receptor-positive early stage breast cancer and correlation with estimation of recurrence risk by breast cancer specialists. Oncologist 16:1520-1526
15. Agullo-Ortuno MT, Lopez-Rios F, Paz-Ares L (2010) Lung cancer genomic signatures. J Thorac Oncol 5:1673-1691
16. Van Laar RK (2012) Genomic signatures for predicting survival and adjuvant chemotherapy benefit in patients with non-small-cell lung cancer. BMC Med Genomics 5:30
17. Cardoso F, Van't Veer L, Rutgers E et al (2008) Clinical application of the 70-gene profile: the MINDACT trial. J Clin Oncol 26:729-735
18. Ramaswamy S, Ross KN, Lander ES, Golub TR (2003) A molecular signature of metastasis in primary solid tumors. Nat Genet 33:49-54
19. Bishop JF, Tracey E, Glass P, Jelfs P, Roder D (2007) Prognosis of subtypes of cancer of unknown primary compared to metastatic cancer. J Clin Oncol 25:18S
20. Luke C, Koczwara B, Karapetis C et al (2008) Exploring the epidemiological characteristics of cancers of unknown primary site in an Australian population: implications for research and clinical care. Aust N Z J Public Health 32:383-389
21. Greco FA, Oien K, Erlander M et al (2012) Cancer of unknown primary: progress in the search for improved and rapid diagnosis leading toward superior patient outcomes. Ann Oncol 23:298-304
22. Hainsworth JD, Rubin MS, Spigel DR, Boccia RV, Raby S, Quinn R (2012) Molecular gene expression profiling to predict the tissue of Origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the sarah cannon research institute. J Clin Oncol doi: 10.1200/JCO2012.43.3755
23. Wang CM, Wang Y, Fan CG et al (2011) miR-29c targets TNFAIP3, inhibits cell proliferation and induces apoptosis in hepatitis B virus-related hepatocellular carcinoma. Biochem Biophys Res Commun 411:586-592
24. Mraz M, Malinova K, Kotaskova J et al (2009) miR-34a, miR-29c and miR-17-5p are downregulated in CLL patients with TP53 abnormalities. Leukemia 23:1159-1163
25. Nigro A, Menon R, Bergamaschi A et al (2012) MiR-30e and miR-181d control radial glia cell proliferation via HtrA1 modulation. Cell Death Dis 3:e360
26. Lee JJ, Drakaki A, Iliopoulos D, Struhl K (2012) MiR-27b targets PPARgamma to inhibit growth, tumor progression and the inflammatory response in neuroblastoma cells. Oncogene 31:3818-3825
27. Thulasingam S, Massilamany C, Gangaplara A et al (2011) miR-27b*, an oxidative stress-responsive microRNA modulates nuclear factor-kB pathway in RAW 264.7 cells. Mol Cell Biochem 352:181-188
28. Al-Nakhle H, Burns PA, Cummings M et al (2010) Estrogen receptor {beta}1 expression is regulated by miR-92 in breast cancer. Cancer Res 70:4778-4784
29. Soon PS, Tacon LJ, Gill AJ et al (2009) miR-195 and miR-483-5p Identified as predictors of poor prognosis in adrenocortical cancer. Clin Cancer Res 15:7684-7692
30. Veronese A, Lupini L, Consiglio J et al (2010) Oncogenic role of miR-483-3p at the IGF2/483 locus. Cancer Res 70:3140-3149
31. Cloonan N, Brown MK, Steptoe AL et al (2008) The miR-17-5p microRNA is a key regulator of the G1/S phase cell cycle transition. Genome Biol 9:R127
32. Schneider B, Nagel S, Ehrentraut S et al (2012) Neoplastic MiR-17-92 deregulation at a DNA fragility motif (SIDD). Genes Chromosomes Cancer 51:219-228
33. Li L, Shi JY, Zhu GQ, Shi B (2012) MiR-17-92 cluster regulates cell proliferation and collagen synthesis by targeting TGFB pathway in mouse palatal mesenchymal cells. J Cell Biochem 113:1235-1244
34. Wu L, Chen Z, Zhang J, Xing Y (2012) Effect of miR-513a-5p on etoposide-stimulating B7-H1 expression in retinoblastoma cells. J Huazhong Univ Sci Technolog Med Sci 32:601-606
35. Lee LW, Zhang S, Etheridge A et al (2010) Complexity of the microRNA repertoire revealed by next-generation sequencing. RNA 16:2170-2180
36. Ripoli A, Rainaldi G, Rizzo M et al (2010) The fuzzy logic of microRNA regulation: a key to control cell complexity. Curr Genomics 11:350-353
37. Fizazi K, Greco FA, Pavlidis N et al. (2011) Cancers of unknown primary site: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 22(Suppl 6):vi64-68